All patients had a pathologically confirmed locally advanced NSCLC according to the 8th AJCC staging system would receive platinum-based doublet chemotherapy and immunotherapy, followed by carbon iron radiotherapy and immunotherapy. The concrete immune checkpoint inhibitor includes durvalumab, sugemalimab, atezolizumab, benmelstobart, pembrolizumab, camrelizumab, toripalimab, tislelizumab, sintilimab, nivolumab, serplulimab, or penpulimab.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Unresectable, locally advanced non-small cell lung cancer (according to the 8th edition of the AJCC staging system).
No prior anti-cancer treatment.
No significant internal medical conditions or major organ dysfunction.
You may not be if
Histological evidence of small cell lung cancer or other primary malignancies
EGFR, ALK, or ROS-1 gene mutations.
Active or prior autoimmune/inflammatory disorders.
Inability to comply with study protocol as judged by the investigator.